CCL5 and melanoma: In addition to BECN1 inhibition, targeting other autophagy-related molecules, such as ATG5 or p62/SQSTM1, or inhibiting melanoma autophagy pharmacologically by chloroquine can similarly induce the expression of CCL5 in melanoma cells and consequently enhance the antitumor capacity of NK cells.